Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the
substantia nigra. Current PD medications treat symptoms; none halt or retard dopaminergic …

Experimental models of dopaminergic neurodegeneration play a critical role in our quest to
elucidate the cause of Parkinson's disease (PD). Despite the recent development of “genetic …

An erratum for this article appears in the January, 2004 issue of Movement Disorders (Mov
Disord 2004; 19: 119). Parkinson's disease (PD) is a common neurodegenerative disorder …

Parkinson's disease is a neurodegenerative disorder of unknown pathogenesis. Oxidative
stress has been proposed as one of several pathogenic hypotheses. Evidence for the …

The present study was designed to examine whether expression of iNOS was involved in
LPS-induced neurodegeneration in rat substantia nigra (SN) and to study the role of NO in …

Parkinson's disease (PD) is a progressive neurological disease caused by selective
degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) …

The 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) model constitutes the best-
characterized toxin paradigm for Parkinson's disease, faithfully replicating most of its clinical …

The novel naphtoxazine derivative and preferential D3 vs D2 receptor agonist, S32504,
restores perturbed motor function in rodent and primate models of antiparkinsonian activity …

It began with a single case of drug abuse in Maryland (1), followed by four reported cases in
California (2) in which young heroin addicts self-injected homemade “synthetic heroin” …

Parkinson's disease (PD) is a neurodegenerative disorder which afflicts more than 1 million
Americans with an estimated 50,000 new diagnoses each year. 1-methyl-4-phenyl-1, 2, 3, 6 …